Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplementary Figure S2 from RETRACTED: Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Home
Publications
Supplementary Figure S2 from RETRACTED: Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Supplementary Figure S2 from RETRACTED: Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Authors:
QX
Qingsheng Xu
Qingsheng Xu
KH
Kaiyuan Huang
Kaiyuan Huang
XM
Xiangqi Meng
Xiangqi Meng
YW
Yuxiang Weng
Yuxiang Weng
LZ
Luyuan Zhang
Luyuan Zhang
LB
Linghao Bu
Linghao Bu
XZ
Xiujue Zheng
Xiujue Zheng
JC
Jinquan Cai
Jinquan Cai
RZ
Renya Zhan
Renya Zhan
QC
Qun Chen
Qun Chen
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
17 June 2026
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1078-0432.32713440
Abstract
Axial, sagittal and coronal gadolinium-enhanced and FLAIR MRI at pre-baseline (A-D). Three months later, MRI demonstrated progressive disease after anlotinib plus temozolomide (E-H).
Keywords
GLIOBLASTOMA AXIAL
RECURRENT GLIOBLASTOMA
SUPPLEMENTARY FIGURE
FLAIR MRI
ANLOTINIB HYDROCHLORIDE
CORONAL GADOLINIUM-ENHANCED
FIGURE
RETRACTED
SAFETY
AXIAL
Related articles
Scroll to top